Even for well-established anti-cancer drugs, it is crucial that their manufacturers understand the current and evolving handling practices at hospital pharmacies since these compounds can be highly toxic and volatile.
 
Bristol Myers Squibb sought to gain such understanding with their popular Taxol® cytotoxic drug - with the goal of adding value by addressing challenges that hospitals may encounter with this product. PDD's research across several European markets revealed several issues during preparation for administration, despite the procedure being performed in a safety chamber.
 
Fluid transfer between containers created several risks of drug exposure from needle-stick and splattering. Furthermore drips and splatters might result in the scrapping of other expensive drugs within the safety chamber.
 
Guided by research insights, PDD designed a unique fluid transfer device that addresses major safety and practicality issues with the development of a telescopic needle mechanism with a self-sealing luer and a hydrophobic vent to prevent aerosolisation.
 
With this patented design, PDD helped Bristol Myers Squibb to expand stakeholder acceptance of Taxol® in oncology departments by making its journey from factory to patient easier and safer.

Learn more about our expertise and work in Medical and Healthcare.
 


News & Insights

27/07/2017

PDD completes its transition to the 2016 version of ISO13485 for Medical Devices.

PDD has completed its planned transition to the latest version of this rigorous international quality assurance standard for medical devices, building on the success of earlier transitions and successful audits to the FDA 21CFR Part 820 in 2015.

18/02/2016

The Role of Human-Centred Design in Healthcare Reform and Transformation

All too often our health care is taken for granted, and we assume it will always be available to serve our community’s needs. The question is “How Healthy are our Healthcare Facilities to handle the diversity of services and to produce healthy outcomes for an expansive and unprecedented market of six (6) living generations – All distinctively different with a diverse set of needs and priorities?” According to Pew Research Centre in 2015, 75.3 million Millennials (18-34) surpassed the number of 74.9 million Baby Boomers (51-69), and Gen X (35-50) is projected to outnumber the Boomers by 2028.